Parnax Lab Ltd

Parnax Lab has shown steady growth in net sales and profitability, with net sales reaching 187.74 Cr in March 2025, up from 163.03 Cr in March 2022. Key financial metrics, including profit after tax and earnings per share, have also improved, reflecting a positive trend in overall performance.

Parnax Lab's latest results show strong revenue growth with net sales of ₹62.60 crores, a 29.45% year-on-year increase, but profitability is a concern due to a declining operating profit margin and a drop in return on equity. Overall, while revenue momentum is positive, the company faces challenges in cost management and profitability.

Parnax Lab has shown steady financial growth, with net sales increasing from INR 89.52 crore in March 2021 to INR 187.74 crore in March 2025, and profit after tax rising from a loss of INR 2.92 crore in March 2020 to a profit of INR 11.54 crore in March 2025. The company has also improved its operating profit and cash flow significantly during this period.

Parnax Lab has shown steady financial improvement from March 2021 to March 2025, with net sales increasing from INR 89.52 crore to INR 187.74 crore, and profit before tax rising from a loss to INR 15.67 crore. The company also improved its operating profit and cash flow, indicating overall positive performance trends.

As of November 10, 2025, Parnax Lab is considered an attractive investment opportunity due to its undervalued status with a PE ratio of 13.34 and strong financial ratios, despite a year-to-date stock decline of 25.27%.

As of November 7, 2025, Parnax Lab is fairly valued with a PE ratio of 13.60 and an EV to EBITDA of 8.35, despite a 29.90% decline in stock performance over the past year, contrasting with a strong 5-year return of 575.46%.

As of November 7, 2025, Parnax Lab is fairly valued with a PE ratio of 13.60 and an EV to EBITDA of 8.35, making it more attractive than overvalued peers like Elitecon International and MMTC, despite a year-to-date decline of -23.81% compared to the Sensex's 6.50%, while maintaining a strong 5-year return of 575.46%.

As of November 7, 2025, Parnax Lab is fairly valued with a PE ratio of 13.60 and an EV to EBITDA of 8.35, making it more attractive compared to peers like Elitecon International and MMTC, despite underperforming the Sensex with a return of -29.90%.

As of November 6, 2025, Parnax Lab's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 13.39, an EV to EBITDA of 8.26, and a competitive PEG ratio of 2.55, despite recent stock performance lagging behind the Sensex.

As of November 4, 2025, Parnax Lab's valuation has shifted from attractive to fair, with a PE Ratio of 14.03, an EV to EBITDA of 8.53, and a ROE of 13.86%, positioning it competitively against peers despite a year-to-date return of -21.43%.

Parnax Lab will announce its results on 14 November 2025.

As of October 20, 2025, Parnax Lab is considered undervalued with an attractive valuation grade, featuring a PE ratio of 13.60, an EV to EBITDA of 8.35, and a ROE of 13.86%, significantly lower than peers like Elitecon International and MMTC, despite a year-to-date stock performance lagging behind the Sensex.

As of October 17, 2025, Parnax Lab is fairly valued with a PE ratio of 13.55 and an EV to EBITDA of 8.33, despite a year-to-date stock decline of -24.08%, indicating it is neither undervalued nor overvalued compared to its peers.

As of October 17, 2025, Parnax Lab is fairly valued with a PE ratio of 13.55 and an EV to EBITDA of 8.33, significantly lower than its peers, despite a year-to-date return of -24.08% compared to the Sensex's 7.44%.

As of October 17, 2025, Parnax Lab is fairly valued with a PE ratio of 13.55 and an EV to EBITDA of 8.33, lagging behind the Sensex with a year-to-date return of -24.08%, while compared to peers, it is neither undervalued nor overvalued.